PCM
AURA icon

Prelude Capital Management’s Aura Biosciences AURA Stock Holding History

Prelude Capital Management’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$87K Sell
13,000
-37,000
-74% -$212K 0.01% 1074
2025
Q4 		$273K Hold
50,000
– – 0.02% 844
2025
Q3 		$309K Buy
+50,000
New +$327K 0.02% 717

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Prelude Capital Management's AURA Position: Q1 2026 in Review

Prelude Capital Management reduced its Aura Biosciences (AURA) stake by 74% in Q1 2026, selling an estimated $212K and leaving 13,000 shares worth $87K. The position accounts for 0.01% of the portfolio, ranked #1074.

Prelude Capital Management first reported a position in AURA in Q3 2025 and has held it in 3 quarters since. The position peaked at $309K in Q3 2025. 126 funds tracked by Wall St. Rank hold AURA as of Q1 2026.

  • Prelude Capital Management held 13,000 shares of Aura Biosciences worth $87K as of Q1 2026.
  • Prelude Capital Management sold 37,000 Aura Biosciences shares in Q1 2026, an estimated $212K.
  • Aura Biosciences made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1074 holding.
  • Prelude Capital Management first reported a position in Aura Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Prelude Capital Management's Aura Biosciences position peaked at $309K in Q3 2025.
  • 126 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.